Sign In | Register
Home > News > Company News

Attending 2017 OTS Annual Meeting

Date Published:2017/9/20 13:41:23

 The 2017 Oligonucleotide Therapeutics Society (OTS) Annual Meeting will be held in Bordeaux, France this September 24th to 27th. The OTS aims to provide opportunities to have communication between the academia and the industry and improve the development of oligonucleotide therapeutics. The chairman of RiboBio scientific advisory board, Dr. Craig Mello, will also attend the 2017 OTS annual meeting, as the keynote speaker. This is RiboBio’s third attendance to this forum and we sincerely look forward to seeing you visit us in our booth.

About RiboBio
Since 2004, RiboBio has been focusing on nucleic acids-based drug discovery and manufacture, established a nation-leading platform in nucleic acids drug development and the first cGMP oligonucleotide manufacturing facility by virtue of our leading-edge technologies. The drug discovery platform has built a complete research and development system from nucleic acids-drug design to animal studies, which included high-throughput design and synthesis laboratory, high-throughput high content screening laboratory, and animal efficacy and pharmacology laboratory, biological analysis and pharmacokinetics laboratory.  We offer the first class CRO services for nucleic acids-based drug discovery. The manufacturing facility has oligonucleotides process development laboratory, GMP oligonucleotides manufacturing suite, and oligonucleotide drugs quality control laboratory. We have provided high quality manufacturing services and CMC services of oligonucleotides drug. In recent years, RiboBio has been completed several oligonucleotide GMP manufacturing projects for several well-known pharmaceutical companies.

Guangzhou RiboBio Co., Ltd.  Copyright © 2015 
Address:13-14/F, Innovation Building C3, 182 Kexue Avenue, Science Park, Guangzhou 510663, China